Litcius/Paper detail

<i>In Vivo</i> Targeting of Escherichia coli with Vancomycin-Arginine

Lewis F. Neville, Itamar Shalit, Peter Warn, Marc H. Scheetz, Jizhou Sun, Madeline B. Chosy, Paul A. Wender, Lynette Cegelski, Jacob T. Rendell

2021Antimicrobial Agents and Chemotherapy23 citationsDOIOpen Access PDF

Abstract

The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC toward Escherichia coli , including β-lactamase expressing Ambler classes A, B, and D, was 8 to 16 μg/ml.

Topics & Concepts

Escherichia coliVancomycinGlycopeptideMicrobiologyArginineIn vivoEnterobacteriaceaeAntibioticsBacteriaEscherichiaBiologyChemistryBiochemistryAmino acidStaphylococcus aureusGeneticsGeneAntimicrobial Peptides and ActivitiesBacteriophages and microbial interactionsAntibiotic Resistance in Bacteria
<i>In Vivo</i> Targeting of Escherichia coli with Vancomycin-Arginine | Litcius